Key points are not available for this paper at this time.
e13601 Background: Management of HER2- EBC continues to evolve with expansion of targeted therapies, including abemaciclib, olaparib, and pembrolizumab, in the adjuvant setting for eligible pts. We sought to identify contemporary practice patterns among HCPs for HER2- EBC and compare them with those of experts using an online interactive decision support tool. Methods: An online decision support tool was developed with input from 5 BC experts to provide tx recommendations for 19 unique pt case scenarios based on considerations including subtype, tx history, and recurrence risk. HCPs entered specific patient criteria along with their intended management for that case, and then were shown 5 expert recommendations. HCPs were asked if the recommendations impacted their intended approach. An analysis of expert recommendations and HCP-selected tx was performed. Results: Between Oct 2023 and Jan 2024, 83 HCPs entered 105 cases. Of the 97 cases where HCPs noted a definitive tx plan, recommendations were discordant from experts in 29%. The most commonly queried cases, expert recommendations, and discordance between HCPs and experts are outlined in the table. Discord with experts was similar among HCP tx plans for cases of TNBC (33%) and HR+/HER2- EBC (27%). HCPs predominantly sought guidance for pts with HR+/HER2- EBC, no g BRCAm, and high-risk disease per monarchE trial criteria (79%), with 22% discordance from expert recommendations. Regardless of BC subtype, the highest level of discord between HCPs and experts (67%) was observed in cases where pts had received neoadjuvant tx and had no residual disease following surgery, although this represents a small subset (n = 12). When asked if the expert recommendations changed their tx choice, 7 of 27 (26%) HCPs who responded indicated that expert recommendations changed their intended tx, whereas 15% noted that there were barriers to implementing those recommendations. Conclusions: These data suggest ongoing challenges with incorporating the newest targeted therapies for high-risk EBC management. Continued education and development of resources for HCPs, including online decision support tools, may be increasingly important as the treatment of EBC continues to evolve. Table: see text
Brandt et al. (Wed,) studied this question.